Latest Industry Insights

In this article, Technology Networks spoke with Dr. Jack Hoppin and Dr. John Babich from Ratio Therapeutics to learn more about the recent radiopharmaceutical revolution.

In this interview, Technology Networks spoke with Dr. Lena Jonsson, product strategy manager at Cytiva, to explore the biological, clinical and technological frontiers shaping the next generation of ADCs.

A new pan-European network will integrate long-read sequencing into clinical practice, improving diagnosis of rare diseases and cancers.

To explore how the CGT landscape is evolving, Technology Networks spoke with Betty Woo, vice president of Cell, Gene and Advanced Therapies at Thermo Fisher Scientific.

In this interview, Asim Siddiqui, senior vice president and scientific fellow at Seer, explores the evolving role of unbiased proteomics in cancer research.

In this article, Cristiana Bercea discusses how large, automated storage solutions are helping companies to save time, unlock greater efficiency and better meet sustainability goals – without increasing risk.

In this interview, Dr. Christian Schafmeister discusses the structural advantages of Spiroligomer molecules, their ability to disrupt protein–protein interactions and their potential applications in cancer therapy and beyond.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and innovative manufacturing strategies are overcoming the key limitations of autologous CAR T-cell therapy.

UK Biocentre is adopting Azenta’s BioArc™ Ultra™, an automated -80°C storage system, to enhance biobanking efficiency and sustainability. With high-density storage and precise temperature control, it safeguards valuable samples.

In this opinion piece, Philipp Koellinger explores the changes required to level the playing field and accelerate both scientific and technological progress.